It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Novo Nordisk and United Laboratories International’s subsidiary, United Biotechnology Co. have entered into a potentially $2 ...

Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

It stressed that while the funding came from the Novo Nordisk Foundation, the project itself would be carried out by ...

Novo Nordisk said it had agreed to license a potential rival to its weight-loss drug Ozempic from a Chinese company. The ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Ben McPoland considers a pair of investments that are performing awfully in his ISA portfolio so far this year. What's gone ...